Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UltraFree DCB is a drug-coated balloon (DCB) catheter used in percutaneous transluminal angioplasty procedures, typically for the treatment of arterial stenosis. It features the proprietary UltraFree coating, designed to minimize early drug flaking during preparation and track, ensuring quick and controlled drug release to the vessel wall. The primary active pharmaceutical ingredient is likely paclitaxel, consistent with standard DCB technologies, although exact drug content is not stated in the available sources. The device is primarily indicated for use in the management of peripheral or coronary artery disease, targeting vessel restenosis or de novo lesions, with the goal of inhibiting neointimal hyperplasia and reducing rates of repeat revascularization.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on UltraFree DCB.